Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Lunde

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Structural Biology|April 8, 2006
Membrane-protein stability in a phospholipid-based crystallization mediumChristopher S Lunde, Shahab Rouhani, Marc T Facciotti, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2012
Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studiesYang Song, Christopher S Lunde, Bret M Benton, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|April 5, 2013
Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutantYang Song, Christopher S Lunde, Bret M Benton, et al.
Journal of Agricultural and Food Chemistry|June 26, 2003
Modes of antifungal action of (2E)-alkenals against Saccharomyces cerevisiaeIsao Kubo, Ken-Ichi Fujita, Aya Kubo, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosisJason E Cummings, Christopher S Lunde, M R K Alley, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureusChristopher S Lunde, Charles H Rexer, Stephanie R Hartouni, et al.
Biochemistry|April 28, 2004
Specificity of anion binding in the substrate pocket of bacteriorhodopsinMarc T Facciotti, Vincent S Cheung, Christopher S Lunde, et al.
Antimicrobial Agents and Chemotherapy|May 28, 2009
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid IIChristopher S Lunde, Stephanie R Hartouni, James W Janc, et al.
Structure (London, England : 1993)|February 12, 2013
Deprotonation of D96 in bacteriorhodopsin opens the proton uptake pathwayTing Wang, Ayla O Sessions, Christopher S Lunde, et al.
Diagnostic Microbiology and Infectious Disease|October 23, 2012
In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumoniaKevin M Krause, Johanne Blais, Stacey R Lewis, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Structural Biology|April 8, 2006
Membrane-protein stability in a phospholipid-based crystallization mediumChristopher S Lunde, Shahab Rouhani, Marc T Facciotti, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2012
Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studiesYang Song, Christopher S Lunde, Bret M Benton, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|April 5, 2013
Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutantYang Song, Christopher S Lunde, Bret M Benton, et al.
Journal of Agricultural and Food Chemistry|June 26, 2003
Modes of antifungal action of (2E)-alkenals against Saccharomyces cerevisiaeIsao Kubo, Ken-Ichi Fujita, Aya Kubo, et al.
Plos Neglected Tropical Diseases|November 27, 2023
Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosisJason E Cummings, Christopher S Lunde, M R K Alley, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureusChristopher S Lunde, Charles H Rexer, Stephanie R Hartouni, et al.
Biochemistry|April 28, 2004
Specificity of anion binding in the substrate pocket of bacteriorhodopsinMarc T Facciotti, Vincent S Cheung, Christopher S Lunde, et al.
Antimicrobial Agents and Chemotherapy|May 28, 2009
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid IIChristopher S Lunde, Stephanie R Hartouni, James W Janc, et al.
Structure (London, England : 1993)|February 12, 2013
Deprotonation of D96 in bacteriorhodopsin opens the proton uptake pathwayTing Wang, Ayla O Sessions, Christopher S Lunde, et al.
Diagnostic Microbiology and Infectious Disease|October 23, 2012
In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumoniaKevin M Krause, Johanne Blais, Stacey R Lewis, et al.
Pageof 2